After years of cutting-edge research in epigenetic regulation, Quimatryx announces that the Chinese National Medical Products Administration (NMPA) has approved its Clinical Trial Application (CTA) for QTX125, a first-in-class, highly selective HDAC6 inhibitor, to begin Phase I clinical trials in patients with advanced solid and hematologic tumors.
QTX125 is a pioneering small molecule designed to selectively inhibit HDAC6, a key epiproteomic regulator involved in multiple cancer-driving pathways. By modulating protein acetylation and disrupting cancer cell survival mechanisms, QTX125 opens a new therapeutic avenue for tumors with high unmet medical need.
In preclinical models, QTX125 has shown:
- Strong anti-tumor activity across multiple solid and hematologic tumor types
- Excellent selectivity for HDAC6 versus other HDAC isoforms
- A favorable safety and pharmacokinetic profile
The first-in-human clinical study will evaluate dose escalation and safety of QTX125 as a single agent and in combination with standard-of-care therapies. The trial will be conducted at leading oncology hospitals in China.
This milestone marks a major step forward in Quimatryx’s mission to bring precision epigenetic and epiproteomic therapies to patients worldwide.